
    
      This is an open-label, multi-center, randomized, Phase 2 study designed to compare the
      efficacy and safety of pegilodecakin in combination with nivolumab versus nivolumab alone in
      participants with stage IV / metastatic wild type non-small cell lung cancer and tumors with
      low tumor expression of PD-L1 (0-49%).
    
  